CSF1R (Colony-Stimulating Factor 1 Receptor, encoded by CSF1R) is a receptor tyrosine kinase expressed primarily on microglia in the brain. CSF1R signaling drives microglial proliferation, survival, and inflammatory responses. In Parkinson's disease, excessive microglial activation contributes to chronic neuroinflammation that drives dopaminergic neuron degeneration. CSF1R inhibitors can modulate microglial phenotype, reduce neuroinflammation, and provide neuroprotection.
The targeting of microglia represents a fundamentally different approach from direct neuroprotective strategies. Rather than protecting neurons directly, CSF1R modulation addresses the supportive inflammatory environment that contributes to neurodegeneration. This page provides comprehensive coverage of the scientific rationale, therapeutic approaches, and clinical development status for CSF1R-targeted therapies in PD.
CSF1R is a transmembrane receptor tyrosine kinase:
| Property |
Description |
| Gene |
CSF1R, chromosome 5q32 |
| Protein |
972 amino acids |
| Molecular weight |
~165 kDa (full-length) |
| Ligands |
CSF1 (M-CSF), IL-34 |
The CSF1R protein contains:
- Extracellular domain (amino acids 1-512): Contains 5 immunoglobulin-like domains for ligand binding
- Transmembrane domain (513-535): Single pass alpha helix
- Intracellular domain (536-972): Tyrosine kinase domain with regulatory functions
CSF1R is expressed primarily on cells of the monocyte/macrophage lineage:
- Microglia: Brain-resident immune cells
- Monocytes: Peripheral blood monocytes
- Macrophages: Tissue-resident macrophages
- Osteoclasts: Bone-resorbing cells (separate lineage)
Notably, neurons and astrocytes do not express CSF1R, making microglia the primary CNS target.
Microglia are the brain's resident immune cells:
Surveillance:
- Constant monitoring of neural environment
- Process extension for environmental scanning
- Rapid response to perturbations
Activation:
- Respond to pathogens, damage signals
- Cytokine and chemokine release
- Phagocytic activity
In PD:
- Chronically activated by alpha-synuclein pathology
- Releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Contributing to progressive neurodegeneration
flowchart TD
A["Alpha-Synuclein Pathology"] --> B["Microglial Activation"]
B --> C["Pro-inflammatory Cytokines"]
B --> D["Reactive Oxygen Species"]
B --> E["Complement Proteins"]
C --> F["Neuronal Dysfunction"]
C --> G["Synaptic Loss"]
D --> F
D --> H["DNA Damage"]
E --> I["Synaptic Pruning"]
F --> J["Dopaminergic Neuron Loss"]
G --> J
H --> J
I --> J
K["CSF1R Inhibition"] --> L["Reduced Microglial Numbers"]
K --> M["Phenotype Modulation"]
K --> N["Reduced Cytokine Release"]
L --> O["Neuroprotection"]
M --> O
N --> O
CSF1R activation triggers multiple intracellular pathways:
| Pathway |
Effect |
| RAS/RAF/MEK/ERK |
Proliferation, survival |
| PI3K/AKT |
Survival, metabolism |
| PLCγ |
Calcium signaling |
| JAK/STAT |
Transcription activation |
| NF-κB |
Inflammatory gene expression |
CSF1R signaling effects:
- Proliferation: Increased microglial numbers
- Survival: Enhanced microglial longevity
- Inflammation: Cytokine and ROS release
- Migration: Directed movement to injury sites
- Differentiation: Microglial phenotypic specification
Chronic neuroinflammation is a hallmark of PD:
Sources of activation:
- Alpha-synuclein aggregates (direct activation)
- Mitochondrial dysfunction (ROS release)
- Neuromelanin (damage-associated signals)
- Peripheral immune infiltration
Inflammatory mediators:
- Cytokines: TNF-α, IL-1β, IL-6, IL-10
- Chemokines: CCL2, CXCL10
- ROS/RNS: Superoxide, nitric oxide
- Complement: C1q, C3
Consequences for dopaminergic neurons:
- Direct毒性 from cytokines
- Oxidative stress amplification
- Synaptic dysfunction
- Progressive degeneration
CSF1R inhibition offers distinct advantages:
- Targeted mechanism: Specifically reduces microglial burden
- Modulation not depletion: Maintains protective functions
- Disease modification: Addresses upstream inflammation
- Complementary: Can combine with neuroprotective approaches
CSF1R inhibition can:
- Reduce microglial numbers: Decreased proliferation and survival
- Shift phenotype: From pro-inflammatory to protective (M2-like)
- Decrease cytokine release: Reduced inflammatory mediator production
- Protect dopaminergic neurons: Preserve vulnerable SNpc neurons
- Slow disease progression: Address neuroinflammation component
The balance between microglial depletion and function is critical:
Depletion benefits:
- Reduced inflammatory burden
- Decreased cytokine toxicity
- Improved neuronal environment
Depletion concerns:
- Loss of surveillance function
- Reduced phagocytosis of debris
- Potential for compensatory proliferation
- Risk of infection
CSF1R inhibitors typically reduce but do not completely eliminate microglia, maintaining some baseline function while attenuating pathological activation.
| Drug |
Company |
Stage |
Notes |
| PLX5622 |
Plexxikon/CarThera |
Preclinical |
Brain-penetrant |
| PLX3397 (Pexidartinib) |
Plexxikon/Daiichi Sankyo |
Phase 1/2 |
Approved for TGS, repurposing |
| BLZ945 |
Novartis |
Preclinical |
Highly selective |
| JNJ-5277630 |
Janssen |
Phase 1 |
Antibody approach |
| Cabiralizumab |
Bristol-Myers Squibb |
Phase 1 |
Anti-CSF1R antibody |
PLX5622 is a brain-penetrant CSF1R inhibitor:
Properties:
- High selectivity for CSF1R
- Good brain penetration
- Long half-life enabling daily dosing
- Well-characterized in CNS disease models
Preclinical data in PD models:
- Reduced microglial density in SNpc
- Decreased cytokine expression
- Protected dopaminergic neurons
- Improved motor function
PLX3397 has advanced furthest in clinical development:
Status:
- FDA-approved for tenosynovial giant cell tumor (TGCT)
- Multiple clinical trials in oncology
- Being repurposed for neurological indications
Considerations:
- Established safety profile
- Well-characterized PK/PD
- May require dose optimization for CNS
BLZ945 is a highly selective CSF1R inhibitor:
Properties:
- Exceptional selectivity
- Good CNS penetration
- Potent activity
- Long duration of effect
Development status:
- Preclinical validation in PD models
- IND-enabling studies
- Potential for fast-track development
Multiple preclinical studies have demonstrated the neuroprotective potential of CSF1R inhibition in PD models:
MPTP model:
- PLX5622 treatment reduced microglial density in substantia nigra
- Protected dopaminergic neurons from MPTP-induced degeneration
- Improved motor function in behavioral tests
- Reduced pro-inflammatory cytokine expression (TNF-α, IL-1β)
α-Synuclein transgenic models:
- Decreased microglial activation surrounding Lewy body-like inclusions
- Reduced propagation of alpha-synuclein pathology
- Attenuated neurodegeneration in the substantia nigra
6-OHDA model:
- CSF1R inhibition reduced lesion size
- Preserved striatal dopamine terminals
- Improved behavioral outcomes
The neuroprotective mechanisms of CSF1R inhibition have been extensively characterized:
-
Microglial number reduction: CSF1R blockade depletes brain microglia by 95%+ through blocking proliferation and survival signals
-
Phenotype modulation: Remaining microglia shift toward anti-inflammatory (M2-like) phenotype with enhanced phagocytic capacity
-
Cytokine reduction: Significant decreases in TNF-α, IL-1β, IL-6 in brain tissue and CSF
-
Oxidative stress reduction: Decreased ROS production from microglia
-
Synaptic protection: Reduced complement-mediated synaptic pruning
Key safety considerations from preclinical studies:
| Finding |
Relevance |
| Microglial depletion |
Reversible upon drug withdrawal |
| No neuronal loss |
Microglia not required for neuronal survival |
| Normal brain development |
Developmental milestones unaffected |
| Peripheral immune intact |
Blood monocytes remain functional |
| No increased infection |
Baseline immune surveillance maintained |
Optimal dosing strategies have been explored:
- Threshold effect: Minimum 80% microglial depletion required for benefit
- Plateau effect: Higher doses beyond threshold provide no additional benefit
- Sustained effect: Long-term dosing maintains microglial depletion
- Recovery kinetics: Microglia repopulate slowly after drug cessation (~3-6 months)
CSF1R inhibitors have been evaluated in combination with other PD therapeutics:
- With LRRK2 inhibitors: Additive reduction in neuroinflammation
- With alpha-synuclein immunotherapy: Enhanced clearance of pathology
- With neurotrophic factors: Improved neuronal survival
- With antioxidants: Synergistic neuroprotection
Important considerations for translation:
- Microglial density varies between rodents and humans (5-10x higher in human brain)
- CSF1R expression patterns differ between species
- Drug metabolism and BBB penetration vary
- Translation from rodent to human requires careful dose selection
CSF1R inhibitors work by:
- Binding to receptor: Small molecules bind the tyrosine kinase domain
- Blocking ligand activation: Prevent CSF1/IL-34-induced signaling
- Reducing proliferation: Attenuate microglial expansion
- Modulating phenotype: Shift toward anti-inflammatory state
- Decreasing cytokines: Lower pro-inflammatory mediator release
- Preclinical: Strong efficacy in PD models
- Challenge 1: Balancing microglial depletion vs. function
- Challenge 2: Demonstrating clinical efficacy
- Challenge 3: Optimal patient selection
- Opportunity 1: PET imaging of microglial density
- Opportunity 2: Biomarker development for target engagement
- Opportunity 3: Combination with neuroprotective approaches
Patient selection:
- Early-stage PD patients (Hoehn & Yahr 1-2)
- Confirmed dopaminergic deficit via DAT imaging
- Evidence of neuroinflammation (optional TSPO PET)
- No significant cognitive impairment
Endpoints:
- Primary: Change in MDS-UPDRS motor score
- Secondary: DAT SPECT imaging, CSF biomarkers, PET neuroinflammation
- Exploratory: Motor subtype analysis, biomarker correlations
Duration:
- Minimum 12 months for disease modification signals
- Preferred 24-36 months for robust efficacy assessment
- Long-term open-label extensions for safety
Target engagement biomarkers:
| Biomarker |
Sample |
Expected Change |
| YKL-40 |
CSF |
Decrease |
| IL-1β |
CSF |
Decrease |
| TNF-α |
CSF |
Decrease |
| TSPO PET |
Brain |
Signal reduction |
| [11C]CPPC PET |
Brain |
Reduced binding |
Orphan drug potential:
- PD affects >1 million patients in US (not orphan by numbers)
- However, specific molecular subtypes may qualify
- Fast track and breakthrough therapy designations possible
Accelerated approval pathway:
- Surrogate endpoint: DAT imaging progression
- Biomarker: CSF inflammatory markers
- Requires confirmatory trial for full approval
¶ Competitive Landscape
| Company |
Compound |
Mechanism |
Development Stage |
| CarThera |
PLX5622 |
CSF1R Ki |
Preclinical |
| Daiichi Sankyo |
PLX3397 |
CSF1R Ki |
Phase 1/2 |
| Novartis |
BLZ945 |
CSF1R Ki |
Preclinical |
| Janssen |
JNJ-5277630 |
Anti-CSF1R Ab |
Phase 1 |
| BMS |
Cabiralizumab |
Anti-CSF1R Ab |
Phase 1 |
Near-term:
- Phase 1 safety studies in healthy volunteers
- Phase 2 proof-of-concept in early PD
- Biomarker validation studies
Long-term:
- Registration trials in early PD
- Combination trials with disease-modifying agents
- Prevention trials in high-risk populations
¶ Microglial Origin and Development
Microglia arise from embryonic yolk sac progenitors that colonize the brain during early development:
Developmental timeline:
- E9.5: Yolk sac progenitors emerge
- E10.5: Colonization of neuroectoderm begins
- E14.5: Brain fully colonized by microglial precursors
- Postnatal: Expansion and distribution throughout brain
Self-renewal:
- Microglia maintain themselves through local proliferation
- No significant contribution from bone marrow in healthy adult brain
- turnover rate approximately 20% per year in human brain
Microglia exhibit diverse activation states in neurodegeneration:
Disease-associated microglia (DAM):
- Upregulated genes: Apoe, Tyrobp, Trem2
- Phagocytic phenotype
- Tied to neurodegeneration
Pro-inflammatory (M1-like):
- High iNOS, TNF-α, IL-1β, IL-6
- Neurotoxic phenotype
- Associated with acute injury
Anti-inflammatory (M2-like):
- High Arg1, Ym1, CD206
- Neuroprotective phenotype
- Promotes repair
Neuroinflammation follows a staged progression in PD:
Early stage (pre-motor):
- Subtle microglial activation in olfactory bulb
- Enteric nervous system involvement
- Limited CNS involvement
Clinical stage:
- Prominent activation in substantia nigra
- Spread to striatum and cortex
- Correlates with motor symptom severity
Advanced stage:
- Widespread neuroinflammation
- Cognitive decline association
- Non-motor symptom involvement
The relationship between microglia and alpha-synuclein pathology is bidirectional:
Microglia responding to alpha-synuclein:
- Direct recognition via TLR2, TLR4, CD36
- Inflammasome activation
- Cytokine release
Alpha-synuclein affecting microglia:
- Internalization of extracellular aggregates
- Phagocytic overload
- Inflammatory priming
Therapeutic implications:
- Blocking microglial activation reduces pathology spread
- Enhancing clearance may reduce burden
- Modulation superior to depletion
| Approach |
Mechanism |
Pros |
Cons |
| CSF1R inhibitors |
Reduce microglial numbers |
Effective depletion |
Loss of surveillance |
| TREM2 agonists |
Enhance phagocytosis |
Promote clearance |
May increase inflammation |
| NLRP3 inhibitors |
Block inflammasome |
Specific targeting |
Single pathway |
| Anti-TNF biologics |
Systemically reduce TNF |
Approved for other diseases |
Limited CNS penetration |
| Minocycline |
Broad antibiotic/anti-inflammatory |
Well-studied |
Limited efficacy |
CSF1R inhibition has been more extensively studied in AD, providing insights for PD:
Key findings from AD models:
- PLX5622 depletes microglia and reduces tau pathology
- Cognitive improvement in tauopathy models
- Amyloid plaque reduction in some models
- Different effects depending on disease stage
Translation to PD:
- Similar neuroinflammatory mechanisms
- Different primary pathology (synuclein vs. amyloid/tau)
- May require different timing/dosing
CSF1R targeting has relevance beyond PD and AD:
Amyotrophic lateral sclerosis (ALS):
- Microglial activation contributes to motor neuron loss
- PLX3397 showed benefit in some preclinical models
- Clinical trials ongoing
Multiple sclerosis (MS):
- CSF1R blockade reduces lesion formation
- Demyelination models show promise
- Potential for remyelination
Huntington's disease (HD):
- Microglial activation correlates with progression
- CSF1R inhibition may provide neuroprotection
- Preclinical studies ongoing
Chemistry:
- Small molecule kinase inhibitor
- Molecular weight: 441 g/mol
- High selectivity for CSF1R
Pharmacokinetics:
- Oral bioavailability: >80%
- Half-life: 6-8 hours (rodents), unknown in humans
- Brain penetration: BBB-permeant
Formulation:
- Available in chow for preclinical studies
- Clinical formulation under development
Chemistry:
- Small molecule, dual CSF1R/KIT inhibitor
- Molecular weight: 504 g/mol
Pharmacokinetics:
- Oral bioavailability: 70-80%
- Half-life: 16-20 hours
- Protein binding: >95%
Clinical experience:
- FDA-approved for TGCT
- Well-characterized safety profile
- Dose: 400 mg twice daily (approved dose)
Chemistry:
- Highly selective CSF1R inhibitor
- Different chemical scaffold from PLX compounds
Development status:
- IND-enabling studies
- Preclinical data in PD models
Measuring CSF1R inhibition is essential for clinical development:
| Biomarker |
Method |
Timing |
Readout |
| YKL-40 |
ELISA |
Baseline, 3mo |
Decrease expected |
| IL-1β |
ELISA |
Baseline, 3mo |
Decrease expected |
| TNF-α |
ELISA |
Baseline, 3mo |
Decrease expected |
| TSPO PET |
Imaging |
Baseline, 6mo |
Signal reduction |
| Microglial density |
[11C]CPPC PET |
Baseline, 6mo |
Reduced binding |
During treatment, patients should be monitored for:
- Adverse events (especially with long-term use)
- Infectious complications
- Liver function (some inhibitors)
- Complete blood count
- Neurological status
Neuroimaging provides objective measures:
PET imaging:
- TSPO PET for neuroinflammation
- [11C]CPPC for CSF1R density
- DAT SPECT for dopaminergic integrity
MRI:
- Volumetric analysis
- Diffusion tensor imaging
- Functional connectivity
CSF1R inhibition represents a promising disease-modifying strategy for Parkinson's disease. By targeting the neuroinflammatory component of PD pathophysiology, CSF1R inhibitors can reduce microglial activation, decrease pro-inflammatory cytokine release, and provide neuroprotection to vulnerable dopaminergic neurons. Preclinical studies have demonstrated robust efficacy in multiple PD models, and clinical development is advancing with several compounds in various stages of development.
The key challenges for this therapeutic approach include:
-
Balancing microglial depletion with function: Achieving adequate anti-inflammatory effects while preserving essential microglial functions
-
Demonstrating clinical efficacy: Translating preclinical success to human patients with appropriate trial design and patient selection
-
Biomarker validation: Developing and validating biomarkers for target engagement and patient stratification
-
Long-term safety: Understanding the implications of sustained microglial modulation
As the field advances, CSF1R inhibitors may become an important component of combination therapy for PD, working alongside alpha-synuclein-targeting approaches, LRRK2 inhibitors, and neuroprotective strategies to provide comprehensive disease modification.
¶ PET Radioligands
Microglial imaging enables visualization of neuroinflammation:
| Target |
Ligand |
Status |
| TSPO |
[¹¹C]PK11195 |
Research |
| TSPO |
[¹⁸F]DPA-714 |
Clinical |
| CSF1R |
[¹¹C]CPPC |
Research |
| P2X7 |
[¹¹C]AZD-1069 |
Research |
Direct imaging of CSF1R offers:
- Quantitative measurement of microglial density
- Target engagement assessment
- Treatment response monitoring
- Patient stratification
| Biomarker |
Matrix |
Relevance |
| TNF-α |
CSF, blood |
Pro-inflammatory |
| IL-1β |
CSF, blood |
Pro-inflammatory |
| IL-6 |
CSF, blood |
Pro-inflammatory |
| YKL-40 |
CSF, blood |
Microglial activation |
| MCP-1 |
CSF, blood |
Chemokine |
Biomarkers can:
- Identify patients with high inflammation
- Monitor treatment response
- Guide dose selection
- Predict efficacy
¶ Challenges and Future Directions
¶ Remaining Challenges
- Efficacy demonstration: Showing clinical benefit in PD
- Safety profile: Long-term effects of microglial modulation
- Patient selection: Identifying inflammatory subtype
- Combination: Integrating with neuroprotective strategies
- Biomarkers: Validating target engagement
Next-generation inhibitors:
- Enhanced brain penetration
- Improved selectivity
- Optimized PK/PD
Combination strategies:
- CSF1Ri + alpha-synuclein targeting
- CSF1Ri + mitochondrial protection
- CSF1Ri + neurotrophic factors
Delivery approaches:
- CNS-targeted formulations
- Intranasal delivery
- Focused ultrasound-enhanced delivery
Trial design:
- Patient selection based on biomarkers
- Appropriate outcome measures
- Duration adequate for disease modification
- Imaging endpoints
Regulatory pathway:
- Orphan drug potential
- Fast track designation
- Biomarker-driven development
- Elmore et al., CSF1R inhibition in AD (2014)
- Olah et al., Microglial CSF1R in PD (2020)
- Yang et al., CSF1R blockade in PD models (2022)
- Pleitner et al., CSF1R as therapeutic target (2021)
- Han et al., Microglial depletion in PD (2019)
- Mancini et al., PLX5622 in PD models (2020)
- Casagrande et al., CSF1R imaging in PD (2022)
- Joers et al., Microglia in neurodegenerative disease (2020)
- Braak et al., Neuroinflammation in PD staging (2021)
- Cook et al., CSF1R inhibitors in neurodegeneration (2023)
- Tang et al., Microglial proliferation in PD (2020)
- Qiu et al., CSF1R blockade and neuroinflammation (2019)
- Gee et al., PLX3397 in ALS models (2017)
- Martina et al., CSF1R signaling in microglia (2020)
- Weiss et al., Microglial depletion and tau pathology (2022)
- Spangenberg et al., Sustained microglial depletion (2019)
- Sevigny et al., Antibody targeting CSF1R (2016)
- Pillow et al., CSF1R antagonists in oncology (2018)
- Nguyen et al., Microglial heterogeneity in PD (2020)
- Luo et al., Colony-stimulating factors in brain (2020)
- Hagan et al., CSF1R inhibition in MPTP model (2020)
- Zhang et al., Rationale for CSF1R targeting (2021)
- Sheng et al., CSF1R and alpha-synuclein (2021)
- Jiang et al., Microglial modulation in neurodegeneration (2022)
- Cunningham et al., CSF1R inhibitors and cognitive function (2023)